The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
David S. Knopman, MD
Advertisement
Professor and Consultant, Department of Neurology, Mayo Clinic
Articles by David S. Knopman, MD
Advertisement
Latest Updated Articles
The Aducanumab Saga and the Future of Antiamyloid Monoclonal AntibodiesPublished: June 13th 2022 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
4
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
5
